APP下载

香连丸治疗溃疡性结肠炎的临床及分子机制研究进展

2025-11-16李莹张早育邓蓉陈佳乐李彦龙

中国药房 2025年20期

中图分类号R965;R969;R975 文献标志码A 文章编号 1001-0408(2025)20-2609-06

DOI 10.6039/j.issn.1001-0408.2025.20.22

Research progress on clinical and molecular mechanisms of Xianglian pils in the treatment of ulcerative colitis

LI Ying',ZHANG Zaoyu',DENGRong,CHEN Jiale',LI Yanlong²(1.Schoolof Integrated Traditional Chinese and Western Medicine,Gansu University of Chinese Medicine,Lanzhou 730o, China;2.Spleen and Stomach DiseaseDiagnosis and Treatment Center,Gansu Provincial Hospital of Traditional Chinese Medicine,Lanzhou 730050,China)

ABSTRACTUlcerativecolitis(UC)isachronicintestinalautoimmunedisease,withclinicalmanifestations includingabdomial pain,diarrea,mucusandbloodystols,anditspathogenesis iscomplex.Theclassic presription Xianglianpills(XL)hasben widelyusedintheclinicaltreatmentofUCinrecentyears.Ithasfewadversereactions,goodpatienttolerance,and shows significantpotentialforclinicalaplication.However,thereiscurrentlynocomprehensiveintegrationofevidenceonitsclinical research and molecular mechanisms.Through a systematicreviewof theclinical researchand molecular mechanisms of XLP inthe treatmentofUC,itisfoundthat XLPanditsmodifiedformulas,whenusedincombination withchemicaldrugs,cansignificantly improvetesymptomsofUCpatientsandreduceintestinalinflammation,withsuperioreficacycomparedtochemicaldrugsalone. Itsmechanismofactioninvolvesregulating pan-apoptosis,immuneresponse,signalingpathways(hypoxia-induciblefactor ∇⋅l∝ , nuclear factor- κB ,etc.),intestinal flora,andrepairing the intestinal mucosalbarrier.Its medicinal materials,monomersandactive componentscanalsopreventthediferentiationofhelperTcells17andrestore thebalanceofM1/M2cellsthroughregulating multiple pathways such as Wnt/β -catenin and Janus kinase/signal transducer and activator of transcription, thereby reducing intestinal damage in UC.

KEYWORDSXianglian pills;ulcerative colitis;clinical research;molecular mechanism;research progress

溃疡性结肠炎(ulcerativecolitis,UC)是炎症性肠病的主要类型之一,是一种局限于黏膜及黏膜下层的慢性肠道自身免疫性疾病,以腹痛、腹泻、黏液便和血便等为常见症状。尽管UC病因尚不明确,但学界普遍认为其发病机制主要涉及遗传易感性、环境暴露、肠道菌群紊乱、肠上皮损伤和免疫失调等方面。当前,临床治疗

UC以缓解症状、维持病情缓解状态为目标,常用药物包括5-氨基水杨酸(又称“美沙拉嗪”)、皮质类固醇和免疫调节剂,这些药物可显著减轻肠道炎症,改善患者的生活质量。2023年我国UC临床实践指南推荐轻中度活动期患者使用美沙拉嗪,中重度活动期患者使用糖皮质激素;急性重度UC需早期识别并及时干预,推荐使用糖皮质激素或生物制剂,且长期维持治疗是关键3。同时,《溃疡性结肠炎中西医结合诊疗指南》将UC分为8种中医证型,并指出,在化学药治疗的基础上联合相应中药汤剂可提高UC的临床疗效。

香连丸(Xianglianpills,XLP)源自《太平惠民和剂局方》,由萸黄连和木香按质量比4:1组成,具有清热燥湿、理气止痛之功效,是治疗湿热泻痫的经典名方。方中,君药为经吴茱萸炮制的黄连,其毒性及寒性均较黄连明显减弱,并可减少黄连因过于苦寒所致的冰伏湿热;臣药木香则擅行气化滞,可止痢疾腹痛;两药合用,辛开苦降、寒热并行,共奏清热燥湿、调畅气机之效,使热清湿化、积滞得下,则诸症自愈。现代药理研究表明,XLP具有抗胃溃疡、抗腹泻、抗UC及抗菌等多种作用,被广泛用于治疗大肠湿热所致的痢疾、泄泻、肠炎和胃炎等疾病。……

登录APP查看全文